News | July 21, 2022
Syngene reports revenue from operations up 8% in Q1 FY 23
Company raises the annual revenue guidance from mid-teens to high teens
Company raises the annual revenue guidance from mid-teens to high teens
Syngene's collaboration with Zoetis started in 2011
The Innopack confex is a perfect platform for exhibitors to demonstrate their latest developments in the fields of pharmaceutical packaging, labelling, drug delivery device design and engineering.
Revenue from operations up 15% to Rs. 758 crore in fourth quarter
He has over 22 years of experience in pharmaceutical sales & business development
Syngene will also build and operate a new dedicated drug development laboratory to accelerate the advancement of Amgen R&D projects
The quarter also saw continued investment in new technologies and the successful implementation of several digitization and automation projects across operations
An amount of Rs. 70.9 crore has been earmarked for funding capital expenditure for the proposed expansion
It strengthens Syngene’s portfolio as a fully integrated custom biomanufacturer with added mammalian and microbial capabilities for clinical and commercial supplies
The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels
Subscribe To Our Newsletter & Stay Updated
